Enleofen Bio is a biotechnology company that focuses on developing first-in-class antibody therapeutics for the treatment of fibrotic human diseases. Following the breakthrough discovery in the importance of interleukin 11 as a main driver of fibrosis, Enleofen was founded as a spin-out from National Heart Centre Singapore, SingHealth and Duke-NUS Medical School with Series A funding to translate research findings into treatments that will improve and save the lives of millions of patients worldwide. We aim to develop our lead antibodies in clinical trials within a two-year time frame with the goal of creating a drug that can be used to treat multiple diseases for which there are currently no treatment options. You can find out more about Enleofen by visiting our website at https://www.enleofen.com/.